healthcare

RayVa Patent Award Sends Apricus Biosciences Inc (APRI) Stock …

Healthcare

RayVa Patent Award Sends Apricus Biosciences Inc (APRI) Stock Trading Up

Apricus Biosciences announces on Tuesday that it has been awarded Rayva’s Patent by USPTO; stock soars by 15.58%
APRI

By: Martin BlancPublished: Jan 28, 2015 at 11:41 am EST

Apricus Biosciences Inc. (NASDAQ:APRI) is trading up by around 15.58% as of 11:14 AM EST. The buying spree on the stock followed the announcement […]

(APRI) Stock Trading Up – Bidness Etc

Healthcare

RayVa Patent Award Sends Apricus Biosciences Inc (APRI) Stock Trading Up

Apricus Biosciences announces on Tuesday that it has been awarded Rayva’s Patent by USPTO; stock soars by 15.58%
APRI

By: Martin BlancPublished: Jan 28, 2015 at 11:41 am EST

Apricus Biosciences Inc. (NASDAQ:APRI) is trading up by around 15.58% as of 11:14 AM EST. The buying spree on the stock followed the announcement […]

Deutsche Bank's Top Biotech Picks For 2015

View photo.Deutsche Bank on Thursday named its top Small-Cap Biotech picks for 2015. The top picks were selected because they were either a disruptive technology, a rare or orphan disease market, an unmet need market or a stock with a big-time catalyst.Here is what to watch for in Deutsche’s top picks.
PTC Therapeutics, Inc. (NASDAQ: PTCT)
Deutsche highlighted PTC Therapeutics as its […]

3 Unusual ETFs With Upside Potential

However, one has to be careful not to grab an ETF that sounds too “cool” or cutting-edge, because it may mean some very illiquid securities are involved and you want to stay away from those.PLUS: 10 Ways to Tax-Proof Your PortfolioInstead, I look for ETFs that are structured in a creative way to distinguish them from other ETFs that are in […]

What Investors Are Looking At In The Stem Cell Sector

What Investors Are Looking At In The Stem Cell Sector
By iCELL News on January 14, 2015 · Sector
Stem cell stocks did poorly in 2014.However, many of these companies have catalysts in the first quarter of 2015 that could bring attention to the sector.In anticipation of a Phase 2 clinical update, Brainstorm Cell Therapeutics IncBCLI 1.89%stock rallied nearly 100 percent. The […]

Better Healthcare Buy: Big or Little Biotechs

Source: Flickr user Chris PotterBiotechnology stocks were among the market’s top performers in 2014, but biotech stocks were also among the market’s riskiest plays. For risk tolerant investors, biotech’s pop-and-drop nature may be enticing, but should investors focus on big or small cap biotech stocks? We asked some of our top Motley Fool analysts for their opinion. Read on to […]

3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015

Source: Flickr via Idaho National Laboratory.Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage companies over the past few years.In 2014, for instance, we saw bluebird bio more than triple in share price after reporting positive early- to mid-stage study results for […]

Biotechs Rally!

Biotechs Rally!Biotech stocks were really strong today. BIIB led the group with a $18.59 pop! ALXN added nearly $10. AMGN gained $5.34, erasing yesterday’s loss. JAZZ climed +3%. ILM popped $6.61.At first glance, BTK looks to be healthyBTK has been consolidating for more than a month. Its daily MAs have bunched together. Just yesterday, BTK was look bearish when it […]

3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015

Sovaldi pill. Source: Gilead SciencesGilead Sciences had another phenomenal year in 2014, returning 26% for investors. That’s more than double the return of the broad-based S&P 500 , and it has hepatitis C drug Sovaldi to thank.In just the first nine months of 2014, Sovaldi netted Gilead $8.55 billion in sales. It’s the most effective drug launch in history by […]

2015 Biotech Stock Preview: Rhythms Of The 'PermaBull' | Seeking …

SummaryBiotech stocks should outperform the market in 2015. However the biotech sector is linked to healthcare fundamentals like government pricing policy.
The industry is better financed than any time in its history driving innovation and new product growth. The appetite for M&A and IPOs will continue.
Biopharmaceutical stocks defy traditional analysis and have been a safe haven from global economic news.
2015: Another […]